“Biologic medicines have extended the lives of women with breast cancer by years and have saved thousands of lives. Additional biologic medicines in the research pipeline offer hope to people with breast cancer and other cancers.
But large pharmaceutical companies are using the Trans-Pacific Partnership (TPP) deal to push for long term monopolies on these medicines and make more money. They seek a delay of at least 8 years before allowing generics or biosimilars. That way they can charge up to hundreds of thousands of dollars per year for the medicines by denying less expensive alternatives that could save lives.”